Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $8.17 Average Price Target from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.1667.

Several equities analysts have weighed in on the company. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Royal Bank Of Canada set a $3.00 price target on Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. Finally, Piper Sandler assumed coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price objective for the company.

Hedge Funds Weigh In On Jasper Therapeutics

Several large investors have recently modified their holdings of JSPR. Velan Capital Investment Management LP raised its position in shares of Jasper Therapeutics by 86.1% in the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after purchasing an additional 1,234,567 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after buying an additional 1,719,602 shares in the last quarter. Acorn Capital Advisors LLC bought a new position in Jasper Therapeutics in the 3rd quarter worth approximately $3,291,000. Millennium Management LLC boosted its holdings in Jasper Therapeutics by 194.2% in the 4th quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after buying an additional 708,844 shares during the period. Finally, Woodline Partners LP purchased a new position in Jasper Therapeutics in the 3rd quarter valued at approximately $2,475,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Up 0.1%

JSPR opened at $0.70 on Monday. The stock has a market cap of $23.29 million, a price-to-earnings ratio of -0.44 and a beta of 3.02. Jasper Therapeutics has a twelve month low of $0.32 and a twelve month high of $2.87. The company’s 50-day moving average price is $0.65 and its two-hundred day moving average price is $0.86.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, sell-side analysts anticipate that Jasper Therapeutics will post -1.32 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.